STOCKS TELEGRAPH

Tag: XTL Biopharmaceuticals

  • Strategic Acquisition Drives XTL Biopharmaceuticals (XTLB) To Nearly Double

    Strategic Acquisition Drives XTL Biopharmaceuticals (XTLB) To Nearly Double

    During the current trading session, the shares of XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) are experiencing a notable surge of 98.06%, culminating in a valuation of $2.04. This remarkable upswing in XTLB shares is directly attributable to a recent strategic acquisition move.

    XTL Biopharmaceuticals (XTLB) announced today its formal agreement with THE SOCIAL PROXY Ltd., delineated within a binding term sheet. The Social Proxy stands as an avant-garde entity specializing in web data solutions, crafting and empowering a distinctive ethical, IP-centric proxy and data extraction platform tailored for AI & BI Applications at scale.

    Pursuant to the Term Sheet, XTLB intends to acquire the entirety of Social Proxy’s issued and outstanding share capital on a fully diluted basis. This acquisition will be executed through a private placement, wherein the Company will issue a certain number of ADS’s representing 44.6% of its issued and outstanding share capital post-issuance, alongside a payment of US$430,000 to Social Proxy’s shareholders.

    Furthermore, as a component of the Transaction, Social Proxy’s shareholders will receive additional warrants, exercisable upon meeting specific financial benchmarks within a three-year timeframe subsequent to the Transaction’s closure. As part of XTL Biopharmaceuticals’ overarching strategy, the proposed transaction complements its asset portfolio with high growth prospects.

    A private placement commitment of US$1,500,000 has been obtained by the Company to strengthen its financial position and expedite the transaction. In exchange for their investment, investors will receive 1,500,000 units, each consisting of one ADS and one warrant that can be exercised for five years after issuance at a price of US$1.20 per warrant.

    Due to the involvement of Mr. Alexander Rabinovich, a director and 23.5% shareholder of the company, the investment is subject to shareholder approval. Following the acquisition, Social Proxy will operate as a fully-owned subsidiary of XTL Biopharmaceuticals, and its shareholders will have the authority to select two of the company’s possible seven board of directors representatives.

  • Is this a bubble or reality: XTL Biopharmaceuticals Ltd (XTLB) stock sky-rocketed in the pre-market session?

    Is this a bubble or reality: XTL Biopharmaceuticals Ltd (XTLB) stock sky-rocketed in the pre-market session?

    NASDAQ listed XTL Biopharmaceuticals Ltd ADR (XTLB)was founded in 1993 and became a public company in 2000. It focuses on the acquisition and development of late-stage medication product candidates for the treatment of unmet clinical needs.

    The Company of the Healthcare sector stock surged dramatically more than 170% to $7.82 in the pre-market session despite no publication was released by the company.

    So, what do we want no know about XTL Biopharmaceuticals (XTLB)?

    The XTLbio pipeline mainly emphasizes systematically identifying, validating, and in-licensing therapeutic candidates with advantages over current therapies and which address unmet medical needs. Today 3 compounds are actively being developed, all in clinical stages.

    • hCDR1 is currently undergoing Phase 3 testing at XTL Biopharmaceuticals, and is on the top of their drug development program. New compound hCDR1, acting through an entirely novel mechanism of action, for the management of Systemic Lupus Erythematosus has been generated. Treatment for SLE currently focuses on immune suppressing drugs, such as azathioprine, cyclosporine, corticosteroids and others.

    One of the most important factors to consider here is that the FDA has only approved a single treatment for SLE in the last 50 years; it is Benlysta (belimumab), approved back in the year 2011.

    • Meanwhile, the Company’s another medicine in process of development is Erythropoietin (rHuEPO), which apparently is in phase 2 of its trial. The development of Recombinant Human Erythropoietin (rHuEPO), a known anemic agent, has the aim of prolonging the survival of patients with advanced Multiple Myeloma. rHuEPO was designated an orphan drug by the FDA in 2011 for the treatment of multiple myeloma blood cancer.

    Finally,

    As biotech companies rely on FDA approvals and feedback, investors in the biotech market must be aware of the fact that there can be a long wait when it comes to investment gains.